The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pharmaceutical Tourism

Pharmaceutical Tourism

November 1, 2009 • By Bruce N. Cronstein, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Several years ago, we took a family vacation with my mother in Greece. My mother, like many patients, managed to forget to bring all of her medications and did not mention this oversight until we had been traveling for several days. Fortunately, we found a pharmacy in Sparta that was able, with the help of pictures, to figure out what medications my mother needed. We were all surprised at how inexpensive the medications, including a number of brand-name drugs, were and my mother took full advantage of this situation to obtain several months’ worth of her medications. Indeed, my mother was so enthusiastic over her bargains that she began thumbing through the pictures in the pharmacist’s catalog asking whether various cheap drugs could help her. We finally put a stop to her shopping frenzy when she asked whether the cyclophosphamide pills that cost practically nothing would be good for her hypertension.

You Might Also Like
  • Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad
  • Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices
  • France Gets G7 to Discuss Global Regulation of Medicine Prices
Explore This Issue
November 2009
Also By This Author
  • The American Board of Bada Bing

The high cost of drugs in this country should be corrected not by reform of the healthcare system but by appropriate trade agreements.

Inequitable Economics of Drugs

If nothing else, this incident illustrates an ongoing irritant for many Americans. Why do we pay so much more for our medications than people pay abroad? Given the difference in prices, the purchase of drugs from Canada is even encouraged by some states to reduce their costs. The obvious and conventional explanation for this price differential is that countries with a central purchasing mechanism—and therefore built-in economies of scale—have much more clout in negotiating prices with the pharmaceutical industry than the United States, where no single entity negotiates the price of drugs. The single-party payers of the industrialized world have another negotiating advantage: as arms of the government, they can also threaten to take away the patent protection for any new drugs. Not selling the drugs at a price that health agencies are willing to pay would deprive their citizens of potentially life-saving interventions and trigger an “emergency” elimination of patent protection so that cheaper generic versions of the drug could be quickly brought to market.

Developing new drugs is an expensive undertaking and not for the faint of heart. Only a small minority of agents successfully makes its way from the laboratory to the clinic. Patent protection with the exclusive right to sell a specific agent over a defined period of time permits the pharmaceutical industry to recoup its development costs and invest in the next potential drug. Thus, limiting the selling price of a new drug in an entire country pushes the pharmaceutical industry to make up for this sales cap where it can. This place is the largely unregulated market of the United States. The clear implication of this analysis is that drug development (and pharmaceutical profit) is largely funded by the patients (taxpayers) of the United States, a clear subsidy for other countries.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Legislation & Advocacy Tagged With: Drugs, Healthcare Reform, TravelIssue: November 2009

You Might Also Like:
  • Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad
  • Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices
  • France Gets G7 to Discuss Global Regulation of Medicine Prices
  • Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.